Homocysteine: Is it a clinically important cardiovascular risk factor?
Steven R. Lentz, MD, PhD
Department of Internal Medicine, University of Iowa; Veterans Affairs Medical Center, Iowa City
William G. Haynes, MD
General Clinical Research Center, University of Iowa, Iowa City
Address: Steven R. Lentz, MD, PhD, Department of Internal Medicine, C303 GH, The University of Iowa, Iowa City, IA 52242; e-mail email@example.com
Dr. Lentz’s work is supported by the Office of Research and Development, United States Department of Veterans Affairs, and National Institutes of Health grants HL63943, NS24621, and HL62984.
Dr. Haynes’ work is supported by National Institutes of Health grants HL58972 and HL14388.
ABSTRACTElevated plasma homocysteine is associated with an increased risk of myocardial infarction, stroke, and venous thromboembolism. Folic acid and other B vitamins lower plasma homocysteine levels, but whether this therapy confers a clinical benefit has yet to be determined. Until we know the results of ongoing clinical trials of homocysteine-lowering therapy, testing for and treating elevated homocysteine is probably justified only in patients with known cardiovascular disease or who are at high risk.